Cancer Advances gets US patent allowance for monoclonal antibodies to progastrin.
M2 PHARMA-April 29, 2014-Cancer Advances gets US patent allowance for monoclonal antibodies to progastrin
(C)2014 M2 COMMUNICATIONS
29 April 2014 - Cancer Advances Inc, a fully-owned biotech portfolio company of US Cato BioVentures, said Tuesday it had received allowance for a US divisional patent covering monoclonal antibodies to progastrin, the unprocessed precursor to the gastrin hormone.
The allowed claims will grant the company exclusive rights to utilise high specificity monoclonal antibodies against progastrin to treat ulcers and cancers. Treatment with these antibodies could decrease the amount of gastrin signaling in patients, thus lowering the effect gastrin has on their disease, the firm noted.
Cancer Advances owns an intellectual property portfolio comprising over a hundred US and global patents concerning Polyclonal Antibody Stimulator (PAS), its lead compound, that has been clinically investigated in three gastrointestinal cancers. PAS is an active immunotherapeutic inducing antibodies against the hormone, gastrin 17 (G17), and its precursor, (gly)G17, which play a key role in the development and progression of gastrointestinal and other tumours.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Date:||Apr 29, 2014|
|Previous Article:||Enzymotec enters into final patent settlement and license agreement with Neptune.|
|Next Article:||Illumina unveils VeriSeq PGS for preimplantation genetic screening of embryos.|